Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice

Bone

Volumn 30, Issue 6, 2002, Pages 909-916

  Stabnov, L ^a,c   Kasukawa, Y ^a   Guo, R ^a   Amaar, Y ^a,b   Wergedal, J E ^a   Baylink, D J ^a,b   Mohan, S ^a,b  

^a Jerry L Pettis Memorial VA Medical Center   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Alendronate; Bone density; Bone size; Insulin like growth factor (IGF 1); MIDI mice; Puberty

Indexed keywords

ALENDRONIC ACID; SOMATOMEDIN C;

ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CONTROLLED STUDY; DRUG EFFECT; GROWTH CURVE; MINIPUMP; MOUSE; MOUSE STRAIN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PERIOSTEUM; PUBERTY;

ALENDRONATE; ANIMALS; BONE DENSITY; DRUG SYNERGISM; FEMALE; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, KNOCKOUT; SEXUAL MATURATION;

EID: 0036274234     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00738-X     Document Type: Article

References (32)

1. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta
2. Association of IGF-I levels with muscle strength and mobility in older women
3. The potentiation of estrogen on insulin-like growth factor-I action in MCF-7 human breast cancer cells includes cell cycle components
4. Short-term effects of recombinant human insulin-like growth factor-1 on bone turnover in normal women
5. Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: A placebo controlled trial
6. The roll of insulin-like growth factor I in age-related changes in calcium homeostasis in men
7. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women
8. IGF-I deficient mice show reduced peripheral nerve conduction velocities and decrease axonal diameters and respond to exogenous IGF-I treatment
9. Alendronate induces antinociception in mice, not related with its effects in bone
10. The insulin-like growth factor system and the coupling of formation to resorption
11. Insulin-like growth factor-1 stimulates bone turnover in osteoporosis
12. Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-I deficiency
13. Studies on the potential mediators of skeletal changes occurring during puberty in girls
14. Determinants of bone density in young women. I. Relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females
15. 3H-etidronate in rat and mouse bones
16. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice
17. Insulin-like growth factor-1 supports formation and activation of osteoclasts
18. Development of valid methods to measure insulin-like growth factors-I and -II in bone cell-conditioned medium
19. Bone growth factors
20. Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids
21. Skeletal changes in mice lacking IGF-I or IGF-II gene: Evidence for a critical role for IGFs in bone accretion during puberty
22. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal women
23. The two faces of growth: Benefits and risks to bone integrity
24. Osteoporosis
25. Postnatal and pubertal skeletal changes contribute predominantly to the differences in peak bone density between C3H/HeJ and C57BL/6J mice
26. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
27. Circulating and skeletal insulin-like growth factor-1 (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities
28. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats
29. Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak skeletal mass
30. Longitudinal monitoring of bone mass accumulation in healthy adolescents: Evidence for a marked reduction after 16 years of age at level of lumbar spine and femoral neck in female subjects
31. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone (1-34) on rat bone
32. Continuous s.c. infusion rather than twice-daily injections of IGF-I more effectively increases serum IGF binding protein-3 in female monkeys